OncoZenge: Engages LINK Medical for feasibility study - Redeye

Redeye comments on OncoZenge’s engagement of LINK Medical to conduct a feasibility study ahead of its European phase III trial for BupiZenge. We view this as a strategically important step in the company's clinical execution plan, aimed at optimizing trial site selection and recruitment timelines in key European markets.

Länk till analysen i sin helhet: https://www.redeye.se/research/1114007/oncozenge-engages-link-medical-for-feasibility-study?utm_source=finwire&utm_medium=RSS